Efficacy of Anidulafungin in the treatment of invasie candida infections in clinical practice
- Conditions
- invasive Candidiasis infectionB37Candidiasis
- Registration Number
- DRKS00000074
- Lead Sponsor
- niversitätsklinik Freiburg
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 37
Inclusion Criteria
invasive mycosis through candida species
Exclusion Criteria
Treatment is compliant with approval of Anidulafungin.
Study & Design
- Study Type
- observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method - ongoing (< 7 days) improvement with regard to underlying disease after donation of Anidulafungin<br>- two negative blood analysis (3-7 days after start with therapy with Anidulafungin, samples to be collected with intervall of 24 h) in case of candidae or no evidence or agent persistence after end of therapy<br>- no necissity to change of antimykotic therapy after within 7 days of start after Anidulafungin treatment<br>
- Secondary Outcome Measures
Name Time Method